Skip to content
DataLookout
Menu

NCT07748767

Micro-nanoplastic Exposure and Coronary Microcirculatory Dysfunction as Well as Cardiovascular Outcomes

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Primary endpoints: details revised at 1 of 2 entries
    • Start date changed from estimate of Jan 1, 2027 to Sep 8, 2026
    • Secondary endpoints: details revised at 1 of 2 entries
  2. Notable Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 2 entries
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Baseline Peripheral Circulatory MNPs Concentration(μg/g, particles/ml)
Timeframe: baseline
Coronary Microvascular Function
Timeframe: baseline

Secondary (2)

2 years Follow-up MACE
Baseline Intracoronary MNPs Concentration(μg/g, particles/ml)

Arms and interventions

Micro-nanoplastic Exposure and CVOT

According to the baseline circulating MNPs exposure level of the patients, participants will be categorized into the high-exposure group and low-exposure group using the median value as the cutoff point.

Other: micro-nanoplastic examination

Procedures: Microvascular Function Examination

Sites

1 site in 1 country

  • Beijing Anzhen HospitalBeijing, China